Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D.

J Clin Oncol. 2017 Jan 10;35(2):175-184. Epub 2016 Nov 7.

PMID:
28056193
2.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
3.

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R; SAKK and the German CML Study Group.

Ann Hematol. 2015 Dec;94(12):2015-24. doi: 10.1007/s00277-015-2494-9. Epub 2015 Sep 18.

PMID:
26385387
4.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group.

Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.

5.

Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.

Fouladi F, Jehn LB, Metzelder SK, Hub F, Henkenius K, Burchert A, Brendel C, Stiewe T, Neubauer A.

Leuk Lymphoma. 2015;56(9):2690-8. doi: 10.3109/10428194.2014.1003055. Epub 2015 Mar 3.

6.

Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.

Burchert A.

Curr Hematol Malig Rep. 2014 Mar;9(1):9-16. doi: 10.1007/s11899-013-0196-8. Review.

7.

Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.

Hoffmann JC, Stabla K, Burchert A, Volkmann T, Bornhäuser M, Thiede C, Neubauer A, Brendel C.

Ann Hematol. 2014 Feb;93(2):279-85. doi: 10.1007/s00277-013-1961-4. Epub 2013 Dec 19.

PMID:
24352219
8.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M.

Lancet Oncol. 2012 Oct;13(10):1035-44. doi: 10.1016/S1470-2045(12)70349-2. Epub 2012 Sep 7.

PMID:
22959335
9.

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib.

Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A.

Blood. 2012 Jan 12;119(2):530-9. doi: 10.1182/blood-2010-08-303495. Epub 2011 Nov 18.

10.

Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.

Wilhelm C, Neubauer A, Burchert A.

Leuk Lymphoma. 2011 Oct;52(10):2031-5. doi: 10.3109/10428194.2011.588760. Epub 2011 Jun 24. No abstract available.

PMID:
21702642
11.

IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia.

Hu X, Yang D, Zimmerman M, Liu F, Yang J, Kannan S, Burchert A, Szulc Z, Bielawska A, Ozato K, Bhalla K, Liu K.

Cancer Res. 2011 Apr 15;71(8):2882-91. doi: 10.1158/0008-5472.CAN-10-2493. Epub 2011 Apr 12.

12.

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A.

J Clin Oncol. 2010 Mar 10;28(8):1429-35. doi: 10.1200/JCO.2009.25.5075. Epub 2010 Feb 8.

PMID:
20142590
13.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM.

Blood. 2009 Dec 17;114(26):5264-70. doi: 10.1182/blood-2009-07-234880. Epub 2009 Oct 7.

14.

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.

Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A.

Blood. 2009 Jun 25;113(26):6567-71. doi: 10.1182/blood-2009-03-208298. Epub 2009 Apr 23.

15.

Roots of imatinib resistance: a question of self-renewal?

Burchert A.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):152-61. Epub 2007 Aug 1. Review.

PMID:
17683977
16.

Diffuse pneumatosis due to central venous catheterization in a patient with acute graft-versus-host disease.

Mikesch JH, Burchert A, Kress O, Ritter M, Görg C, Neubauer A.

Ann Hematol. 2007 Oct;86(10):767-9. Epub 2007 Jun 16. No abstract available.

PMID:
17572894
17.

Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells.

Dror N, Rave-Harel N, Burchert A, Azriel A, Tamura T, Tailor P, Neubauer A, Ozato K, Levi BZ.

J Biol Chem. 2007 Feb 23;282(8):5633-40. Epub 2006 Dec 22.

18.

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.

Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A.

Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7.

19.

Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells.

Hofbauer LC, Schrader J, Niebergall U, Viereck V, Burchert A, Hörsch D, Preissner KT, Schoppet M.

Thromb Haemost. 2006 Apr;95(4):708-14.

PMID:
16601843
20.

Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.

Ortmann CA, Burchert A, Hölzle K, Nitsche A, Wittig B, Neubauer A, Schmidt M.

Nucleic Acids Res. 2005 Dec 7;33(21):6895-905. Print 2005.

Supplemental Content

Loading ...
Support Center